ALS Therapy Development Institute (ALS TDI) believes that ALS is not an incurable disease, it is an underfunded one. As the world’s foremost drug discovery center focused solely on ALS, they have a team of 36 scientists whose singular purpose is to develop and test potential therapies, to slow the progression of the disease and work in pursuit of a cure.

Orr Group’s partnership with ALS TDI began after the organization had undergone numerous changes in leadership within their administrative departments, including marketing, development, IT and finance. Unable to dramatically increase their revenue for a number of years, ALS TDI engaged Orr Group to determine the cause.

As part of the assessment, Orr Group reviewed all of ALS TDI’s internal governance documents, their staff and leadership structure and external communications. We interviewed ALS TDI’s executive leadership, staff members and external stakeholders, including members of the Board of Directors. These interviews helped us better understand the state of philanthropy and corporate culture at ALS TDI. In addition, we conducted an environmental scan of two comparable organizations to understand the philanthropic landscape for neuro-degenerative diseases and how other organizations were achieving their fundraising targets.

Orr Group’s assessment revealed a need for more streamlined processes, increased staff training and access to resources as well as an increased focus on philanthropy within their corporate culture. Following the completion of our assessment, ALS TDI has continued to partner with Orr Group to assist in streamlining their events processes to facilitate better external relations. Orr Group also continues to assist in training and coaching their staff and executive leadership on best practices in fundraising, organizational planning and management.

Orr Group partnered with ALS TDI to assess its culture of philanthropy and developed a roadmap focused on strengthening the organization’s capacity to scale.